Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Maria Fleseriu is an Endocrinologist in Portland, Oregon. Fleseriu has been practicing medicine for over 30 years and is rated as an Elite expert by MediFind in the treatment of Acromegaloid Facial Appearance Syndrome. She is also highly rated in 24 other conditions, according to our data. Her top areas of expertise are Acromegaly, Cushing's disease, Pituitary Tumor, Cushing's syndrome, and Hormone Replacement Therapy (HRT). Fleseriu is currently accepting new patients.
Monica Gadelha practices in Rio De Janeiro, Brazil. Gadelha is rated as an Elite expert by MediFind in the treatment of Acromegaloid Facial Appearance Syndrome. She is also highly rated in 13 other conditions, according to our data. Her top areas of expertise are Acromegaly, Hypertrichosis-Acromegaloid Facial Appearance Syndrome, Acromegaloid Facial Appearance Syndrome, and Pituitary Tumor.
Andrea Giustina practices in Milan, Italy. Giustina is rated as an Elite expert by MediFind in the treatment of Acromegaloid Facial Appearance Syndrome. She is also highly rated in 20 other conditions, according to our data. Her top areas of expertise are Hypertrichosis-Acromegaloid Facial Appearance Syndrome, Acromegaloid Facial Appearance Syndrome, Acromegaly, Pituitary Tumor, and Hormone Replacement Therapy (HRT).
Summary: There is a variety of tumors affecting the pituitary gland in childhood; some of these tumors (eg craniopharyngioma) are included among the most common central nervous system tumors in childhood. The gene(s) involved in the pathogenesis of these tumors are largely not known; their possible association with other developmental defects or inheritance pattern(s) has not been investigated. The present...
Summary: A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with non-pharmacologically treated acromegaly.